Mit einem my.chemie.de-Account haben Sie immer alles im Überblick - und können sich Ihre eigene Website und Ihren individuellen Newsletter konfigurieren.
Luminescent Downshifting Layers Using Organic Dyes and Quantum Dots
The use of an analytical model on luminescent downshifting layers (LDSLs) has been used to estimate the short‐circuit current. Various LDSL have been tested with two different polymers and luminescent materials. These devices have been coupled with a CIGS solar cell. The CdSe/ZnS quantum dots (QD) and Lumogen organic dyes are added in a polymeric scaffold to do a luminescent waveguide increasing the absorption in the UV range. The experimental short‐circuit current are compared to the calculated short‐circuit current. In this model, only the effects of the dyes were taken into account. It has been demonstrated a good correlation between the experimental and the theoretical values. Moreover, different coupling architectures have been experimented. The impact of the interface between LDSL and the solar device is not negligible. It has been experimentally proved the interface change can improve about 40–80% with an ethanol interface. The increase can reach 60–90% with a glycerine interface. The change of this interface impacts directly on the scattering effects and decrease the losses due to the surface defects.
A luminescent downshifting layer (LDSL) is made of a polymeric matrix containing fluorescent materials. Lumogen (BASF) organic dyes and CdSe/ZnS quantum dots are the two materials studied for their downshifting properties. These LDSLs coupled with a solar cell permit to enhance their electrical properties. An analytical model is used to understand the behaviour of the LDSLs coupled with a CIGS solar cell.
Abstract
Congenital myasthenic syndromes (CMS) are heterogeneous disorders in which the safety margin of neuromuscular transmission is impaired by one or more specific mechanisms. Since the advent of next‐generation sequencing methods, the discovery of novel CMS targets and phenotypes ha ... mehr
Abstract
Myasthenia gravis (MG) with antibodies to muscle‐specific kinase (MuSK) is characterized by fluctuating fatigable weakness. In MuSK MG, involvement of bulbar muscles, neck, and shoulder and respiratory weakness are more prominent than in acetylcholine receptor (AChR) MG. MuSK au ... mehr
Abstract
Because of the failure of many promising therapeutics identified in preclinical evaluation, funding sources have established guidelines for increased rigor in animal evaluations. The myasthenia gravis (MG) community of scientists has developed guidelines for preclinical assessme ... mehr
John Wiley & Sons, Inc. stellt die Datenbank SpecInfo erstmals über die dynamische Internet-Plattform Wiley InterScience online zur Verfügung. Mit über 434 000 regelmäßig gepflegten Einträgen gehört SpecInfo zu den weltweit größten Spektrensammlungen.
SpecInfo bietet dem Benutzer eine int ... mehr